AOD 9604: What the Research Actually Shows About This HGH Fragment

What Is AOD 9604 and How Does It Differ from Full HGH?

AOD 9604 is the last 16 amino acids of the 191-amino-acid human growth hormone molecule. Researchers at Monash University isolated this fragment in the 1990s after observing that the C-terminal region of HGH appeared responsible for fat metabolism, while the N-terminal region drove IGF-1 production and the anabolic and diabetogenic effects people associate with exogenous HGH use. The practical implication: AOD 9604 was designed to stimulate lipolysis without raising blood glucose, without suppressing the hypothalamic-pituitary axis, and without the tissue-growth effects linked to elevated IGF-1 [1].

Full recombinant HGH (somatropin) binds the growth hormone receptor, triggering downstream IGF-1 release from the liver. That pathway builds muscle and bone, but it also drives insulin resistance and carries a black-box warning for use in patients with active malignancy. AOD 9604, by contrast, does not bind the classical GH receptor with meaningful affinity. Animal data published in the American Journal of Physiology showed that the fragment activated a beta-3 adrenergic receptor-like mechanism in adipocytes, increasing fat oxidation in obese mice without altering fasting glucose or serum IGF-1 [2]. That mechanistic distinction is why Metabolix Pharma (later Calzada Limited) pursued it as an anti-obesity drug rather than a growth hormone replacement.

The peptide sequence runs from histidine at position 176 to cysteine at position 191, which is why you will see it listed as "HGH Frag 176-191" interchangeably with AOD 9604 across research and commercial channels. Both names refer to the identical structure.

What Did the Clinical Trials Actually Find?

Phase II results were encouraging enough to continue development, but they did not cross the bar required for Phase III approval. The key Metabolin clinical program enrolled obese adults (BMI >27) across three separate 12-week, double-blind, placebo-controlled trials evaluating oral AOD 9604 at doses ranging from 1 mg to 30 mg per day [3].

The most frequently cited result from that program: the 1 mg oral dose arm produced approximately 2.76 kg of weight loss versus 0.84 kg in placebo over 12 weeks in one of the trials. That difference did not reach statistical significance across the pooled program. Metabolix reported a P-value of 0.07 in the primary endpoint analysis, falling short of the conventional P<0.05 threshold [3]. The FDA declined to grant approvable status, and Phase III was never initiated.

Subcutaneous injection data in humans is notably thin. Most injectable dosing protocols cited in forums and telehealth marketing extrapolate from the oral trials or from rodent studies. The mouse work published in Endocrinology showed 50% greater reduction in body fat mass with injected AOD 9604 vs. saline over 7 weeks, but interspecies dose scaling makes those numbers unreliable for clinical guidance [2].

One important finding did hold up: across all Phase II arms, AOD 9604 did not raise fasting insulin, HbA1c, or IGF-1 compared to placebo. That safety signal supports the proposed mechanism and distinguishes it from somatropin, but the absence of harm is not the same as proof of benefit.

The HealthRX medical team uses a three-tier evidence framework when evaluating off-label peptides. Tier 1 means at least one completed Phase III RCT with a primary endpoint met. Tier 2 means completed Phase II with a signal but no Phase III. Tier 3 means preclinical or case-series only. AOD 9604 sits at Tier 2. That places it above purely experimental compounds like some myostatin inhibitors (Tier 3) but well below semaglutide (Tier 1, STEP-1 N=1,961 to 14.9% mean body weight loss at 68 weeks vs. 2.4% placebo) [4]. Patients considering AOD 9604 for weight loss should understand that gap in evidence before committing to a protocol.

How AOD 9604 Is Used Off-Label: Dosing and Protocols

Clinical trial doses were oral and ranged from 1 mg to 30 mg daily. Injectable off-label use follows an entirely different pharmacokinetic model because the peptide bypasses first-pass hepatic metabolism. Subcutaneous bioavailability for HGH fragments of this size runs 60-80% based on structural analogs, though no published pharmacokinetic study has formally characterized injectable AOD 9604 absorption in humans.

The protocol most commonly cited in peptide-prescribing literature: 300 mcg subcutaneous injection once daily, administered in a fasted state (at least 3 hours post-meal), rotating abdominal injection sites, for cycles of 8-12 weeks. Some protocols extend to 500 mcg, citing the oral-to-injectable dose conversion. Neither dose nor cycle length has been validated in a human RCT.

Timing with food matters mechanistically. Beta-3 adrenergic receptor activation drives fatty-acid mobilization from adipocytes. Elevated insulin (from a recent meal) suppresses lipolysis through phosphodiesterase-3B activation, potentially blunting the peptide's intended effect. Fasted administration is therefore pharmacologically logical, even if the clinical magnitude of that interaction has not been quantified in AOD 9604-specific studies.

Reconstitution of lyophilized AOD 9604 requires bacteriostatic water (0.9% benzyl alcohol in sterile water). Standard practice: add 2 mL of bacteriostatic water to a 2 mg vial to yield a 1 mcg per microliter (1 mg/mL) solution. A 300 mcg dose then equals 0.3 mL drawn into an insulin syringe. Refrigerate at 2-8°C after reconstitution; discard after 28 days.

Side Effects and Safety Considerations

The Phase II data reported no serious adverse events attributable to AOD 9604 across any dose arm. Common adverse events (incidence above 5%) included injection-site reactions (redness, transient induration), mild fatigue, and headache, none significantly different from placebo rates [3]. No abnormalities in thyroid function, lipid panels, or liver enzymes were detected at 12 weeks.

What the trials did not study is just as telling. Twelve weeks is insufficient to detect peptide-driven receptor desensitization, antibody formation against the fragment, or effects on proliferative tissue over longer exposure. Growth hormone peptides as a class can theoretically drive proliferation in micrometastatic disease, a concern carried from the somatropin literature. No carcinogenicity study for AOD 9604 has been published in humans [5].

Patients with a personal or family history of colorectal polyps, breast cancer, or pituitary adenomas should discuss this class of peptides with an oncologist before initiating any off-label protocol. The precautionary basis here is biological plausibility, not demonstrated AOD 9604-specific carcinogenicity.

Drug interactions are poorly characterized. Insulin and sulfonylureas theoretically blunt lipolytic effect (the insulin-lipolysis antagonism described above). Concurrent GLP-1 receptor agonists like semaglutide or tirzepatide already suppress appetite and improve metabolic efficiency; whether stacking AOD 9604 adds incremental fat oxidation or merely compounds cost and injection burden is unknown and not supported by any published combination study.

HGH Fragment 176-191 vs. Melanotan I and Melanotan II

Three peptides often appear together in discussions of "research peptides": AOD 9604, Melanotan I (afamelanotide), and Melanotan II. They share a peptide identity but differ sharply in mechanism, regulatory status, and risk profile.

Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that binds MC1R with high affinity. It received European Medicines Agency approval in 2014 under the brand name Scenesse for erythropoietic protoporphyria (EPP), a rare photodermatosis. Approved dose: 16 mg subcutaneous implant every 60 days [6]. Outside EPP, it remains unapproved. Its mechanism has nothing to do with fat metabolism; it acts at melanocortin receptors to increase cutaneous photoprotective pigmentation.

Melanotan II (MT-II) is an older, non-selective melanocortin receptor agonist hitting MC1R, MC3R, MC4R, and MC5R. MC4R activation drives the two effects that created its underground market: spontaneous erections and appetite suppression. MT-II has no approved indication anywhere in the world. The FDA issued multiple warning letters to suppliers between 2012 and 2021 [7]. Documented risks include hypertension from vasoconstriction via MC4R, involuntary sustained erections (priapism) requiring emergency intervention, nausea severe enough to cause dehydration, and several reported cases of rapid progression of pre-existing melanocytic nevi [8]. The risk profile is meaningfully worse than AOD 9604, and clinicians should not treat the two as equivalent just because both are labeled "research peptides."

Melanotan II risk summary: the combination of unregulated sourcing, no approved dose, MC4R-mediated cardiovascular effects, and documented nevi changes makes MT-II among the higher-risk compounds in this category. Patients who present already using it should be counseled to discontinue and have a full-body dermatological examination.

Myostatin Inhibitors: A Brief Comparison

Myostatin (GDF-8) is a TGF-beta superfamily member that suppresses skeletal muscle growth. Inhibiting it, at least in animal models, produces dramatic muscle hypertrophy. That biology made myostatin inhibitors attractive targets for both rare muscle-wasting diseases and, in the performance space, body composition optimization.

Bimagrumab, a human anti-ActRII antibody that blocks activin receptor signaling (the downstream pathway myostatin uses), completed a Phase II trial in type 2 diabetes patients with obesity. At 48 weeks, bimagrumab produced a 20.5% reduction in fat mass and a 3.6% increase in lean mass vs. placebo in 58 subjects (P<0.001 for fat mass) [9]. That is the strongest body-composition signal in this peptide/biologic class and led to a Phase IIb program. Bimagrumab is not approved, not available through telehealth, and not a peptide in the strict sense (it is a monoclonal antibody).

Follistatin-344, YK-11, and similar compounds circulating in research and gray-market channels have no human RCT data. Follistatin-344 is a 344-amino-acid glycoprotein that binds and neutralizes myostatin; at pharmacological doses it also affects activin A, with downstream effects on FSH suppression and reproductive axis disruption. No safety data in humans outside of gene-therapy trials for Becker muscular dystrophy exist [10]. Patients asking about myostatin inhibitors for physique purposes should be directed to the bimagrumab Phase II data, then advised that no approved agent in this class exists for that indication.

Regulatory and Legal Status

AOD 9604 holds FDA GRAS status for oral use as a food additive, a designation granted in 2014 based on the oral safety data from the Phase II program. That designation does not extend to injectable use, does not constitute drug approval, and does not authorize any medical claims. The GRAS notice (GRN 000551) is publicly searchable on the FDA's GRAS database [11].

Injectable AOD 9604 sold by compounding pharmacies falls under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The FDA's November 2023 draft guidance on bulk drug substances for compounding identified several peptides for heightened scrutiny. Prescribers operating under 503A (patient-specific compounding) remain legally exposed if the compound is determined to meet the definition of "essentially a copy" of an unapproved drug [12]. Patients should verify that any prescriber providing AOD 9604 holds a valid state medical license and that the compounding pharmacy holds current PCAB accreditation or state board licensure.

What Clinicians at HealthRX Consider Before Prescribing

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends GLP-1 receptor agonists as first-line agents when pharmacotherapy is indicated, citing the evidence base from STEP-1, SURMOUNT-1, and related trials [13]. The guideline explicitly states: "Agents with inadequate evidence for efficacy or safety should not be offered as primary treatment for obesity."

That framing places AOD 9604 outside first-line or second-line obesity treatment. HealthRX physicians may consider it in patients who meet all of the following criteria: they have failed or are intolerant to approved pharmacotherapy; they have no personal or family history of GH-sensitive malignancy; they understand the Phase II-only evidence base; and they accept the monitoring protocol (baseline and 12-week fasting metabolic panel, CBC, IGF-1, and fasting insulin).

Monitoring during an AOD 9604 cycle: IGF-1 level at baseline and week 8 (expected to remain within normal limits; any elevation above age-adjusted normal should prompt discontinuation), fasting glucose and insulin at baseline and week 8, and injection-site inspection at each follow-up. Dermatological baseline photography is recommended for patients with more than 50 melanocytic nevi, not because AOD 9604 has melanocortin activity, but because the patient demographic often overlaps with individuals who have used or are considering MT-II.

A 12-week cycle at 300 mcg/day yields an expected peptide dose of approximately 25 mg total. Based on the Phase II oral data, where 1 mg daily (84 mg total over 12 weeks) showed a trend toward 2-3 kg fat loss without reaching significance, injectable dosing at 25 mg total is likely pharmacologically sub-threshold by oral-equivalent comparison, though the superior bioavailability of subcutaneous delivery may partially compensate. That arithmetic alone should temper expectations.